TherapeuticsMD (TXMD) Breathtaking Hormone Therapy; Ocean Rig UDW (ORIG) Surpasses Estimates


Shares of TherapeuticsMD, Inc. (NYSEMKT:TXMD) climbed more than 40% to touch a new 52-week high in after-hours trading Monday as the company reported top-line data from a late-stage trial evaluating its TX-004HR at different doses versus placebo for the treatment of moderate-to-severe dyspareunia – a painful sexual intercourse – in postmenopausal women with vulvar and vaginal atrophy

TXMD stock closed the regular session at $6.53, down $0.34 (or -4.95%), with a total volume of 1,897,328 shares traded during the day, increased activity versus its average volume (3m) of 1,108,260

TherapeuticsMD, an innovative women’s healthcare company, has 177.80M Shares Outstanding. At close on Monday, TherapeuticsMD had a Market Capitalization of $1.16B and TXMD stock 52-week range was between $3.44 and $8.83 per share


Ocean _Rig_ORIG

The price of Ocean Rig UDW Inc. (Nasdaq:ORIG) stock soared over 17% in the extended session Monday after the company delivered a solid quarter in its financial results with profit numbers that exceeded projections from analysts.

For the third quarter 2015, Ocean Rig posted revenues of $437.2 million and net income (excluding non-recurring items) of $86.2 million, or $0.58 per diluted share, surpassing the Capital IQ Consensus Estimate of $0.42 earnings per share for the period

ORIG stock touched a new 52-week low of $1.42 in intraday trading to finally close at $1.51, down $0.22 (or -12.72%), and 2,417,735 of its shares exchanged hands during the day

Ocean Rig UDW, an international contractor of offshore deepwater drilling services, has 160.89M Shares Outstanding, Market Capitalization (intraday) of $242.94M and ORIG stock one-year range is from $1.42 to $10.00 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at